Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Step by step instructions to Choose the Right Internet based Degree Program for Your Future - 2Jillian Michaels put me at the center of a body positivity debate. She's not entirely wrong about obesity.
- 3Why ordering takeout or calling the dog walker might lead to a happier relationship
- 4Pick Your #1 Sort Of Espresso
- 5Report: Thailand strikes deal with Iran for safe passage of Hormuz
- Islamic State group militants claim capture and execution of a Nigerian brigadier general
- Massive supernova explosion may have created a binary black hole
- 6 Shades Brands For Seniors
- 10 Demonstrated Systems to Develop Your Internet based Business
- Aid sent by ambulance to Ukraine front line
- NASA's SPHEREx telescope completes its 1st cosmic map of the entire sky and it's stunning!
- Attacks on Iran's Bushehr nuclear plant and on Iraq border crossing
- Army commander convicted of Guinea stadium massacre dies in prison
- Shakira's 2026 'Las Mujeres Ya No Lloran' U.S. Tour: How to get tickets, prices, dates and more
